LONDON, November 17, 2016 /PRNewswire/ --
Deborah I Friedman, US Neurology , 2016;12(2):84-9: https://doi.org/10.17925/USN.2016.12.02.84
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO ) Published recently in US Neurology, the peer-reviewed journal from touchNEUROLOGY, Deborah I Friedman discusses a new treatment in migraine. This condition remains a common debilitating
The full peer-reviewed, open-access article is available here:
Disclosure: Deborah I Friedman is a consultant for Allergan, Avanir, Supernus, Teva Pharmaceuticals, Eli Lilly, Zosano, and Alder Biopharmaceuticals. She is a speaker for Avanir, Supernus, Teva Pharmaceuticals and has received research support from Merck, Autonomic Technologies, Inc., and Eli Lilly.
Note to the Editor
touchNEUROLOGY (a division of Touch Medical Media) publishes
US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
For inquires please contact: Carla Denaro - Managing Editor firstname.lastname@example.org Providing practical opinion to support best practice for busy healthcare professionals
Subscribe to our Free Newsletters!